Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Denali Therapeutics Inc. announced new interim data from the ongoing open-label, single-arm Phase 1/2 study of DNL310 in children with MPS II . DNL310 is an investigational enzyme replacement therapy.
(CNN) — Mothers who followed the Mediterranean diet while pregnant improved their children’s cognitive, social and emotional development at age 2 compared with children whose mothers did not follow the